Proof of concept for claudin‐targeted drug development
Proof of concept for claudin‐targeted drug development
复制标题
DOI：
10.1111/j.1749-6632.2012.06503.x
复制
发表时间：
2012-07
影响因子：
5.2
通讯作者：
Hidehiko Suzuki;M. Kondoh;A. Takahashi;K. Yagi
中科院分区：
文献类型：
--
作者：
Hidehiko Suzuki;M. Kondoh;A. Takahashi;K. Yagi
紧密连接蛋白（Claudin，CL）是一个四整合膜蛋白家族，是紧密连接的关键结构和功能组分。CL在某些恶性肿瘤中过表达。Claudin-4在覆盖粘膜免疫组织的上皮细胞中高度表达。因此，CL可能是一个潜在的目标，以改善药物吸收，治疗癌症，并开发粘膜疫苗。使用产气荚膜梭菌肠毒素的研究为CL靶向药物开发提供了概念证明。一个平台的创建CL结合剂，如免疫CL和CL蛋白的制备，现在开始建立。
Claudins (CLs) are a family of tetra‐integral membrane proteins that are a key structural and functional component of tight junctions. CLs are overexpressed in some malignant tumors. Claudin‐4 is highly expressed in the epithelial cells covering mucosal immune tissues. CLs may therefore be a potential target for improving drug absorption, treating cancer, and developing mucosal vaccine. Research using Clostridium perfringens enterotoxin has resulted in proofs of concept for CL‐targeted drug development. A platform for the creation of CL binders, such as immunization of CL and preparation of CL proteins, is now beginning to be established.